ストックスクリーナーアプリを入手
11.55
2.30%
0.26
プレマーケット:
11.60
0.05
+0.43%
前日終値:
$11.29
開ける：
$11.22
24時間の取引高:
879.95K
Relative Volume:
0.64
時価総額：
$883.79M
収益：
$31,000
当期純損益:
$-54.42M
株価収益率:
-11.81
EPS:
-0.9778
ネットキャッシュフロー:
$-48.99M
1週間 パフォーマンス:
+1.85%
1か月 パフォーマンス:
-10.19%
6か月 パフォーマンス:
+140.12%
1年 パフォーマンス:
+112.71%
1日の値動き範囲:
$10.85
$11.59
1週間の範囲:
$10.78
$12.01
52週間の値動き範囲:
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
Compare CADL vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
11.55 | 883.79M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-28 | 開始されました | Stephens | Overweight |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-30 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-20 | 開始されました | Citigroup | Buy |
| 2025-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-07 | 開始されました | BofA Securities | Buy |
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics upgraded to Strong Buy afte... - Pluang
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL) - Seeking Alpha
H.C. Wainwright Remains a Buy on Candel Therapeutics (CADL) - The Globe and Mail
Candel Therapeutics stock jumps on BofA upgrade to buy - Investing.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics stock jumps on BofA upgrade to buy By Investing.com - Investing.com South Africa
BofA upgrades Candel Therapeutics stock rating on prostate cancer progress - Investing.com
Why is Candel Therapeutics stock surging today? By Investing.com - Investing.com Canada
BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18 - marketscreener.com
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics Inc (NASDAQ:CADL) Share Price | RNS News, Quotes, & Charts | CADL | - Proactive financial news
Candel Therapeutics at H.C. Wainwright conference: prostate cancer push By Investing.com - Investing.com India
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
CADL Slides As Candel Therapeutics Posts Wider Q2 Loss - StocksToTrade
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - manilatimes.net
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
CADL Q2 2026 Earnings: EPS of -$0.52 Misses Consensus by 115.41% as Shares Decline 3.41%Quarterly Financial Update - careplusvn.com
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Biotech Stocks At 52-Week HighsNEO, BLSM, RVMD, ORMP, CADL - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - manilatimes.net
Candel (CADL) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Stock Move: The Share Price Adds 6.32% in the Latest ReadingHealthcare Earnings Report - careplusvn.com
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):